MichelleL.MellionMD
Neurology • Providence, RINeurophysiology
Assistant Professor, Neurology, Brown University Program in Medicine
Dr. Mellion is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2 Dudley St
Suite 555
Providence, RI 02905Phone+1 401-444-3032Fax+1 401-444-3205- Is this information wrong?
Education & Training
Brown UniversityFellowship, Clinical Neurophysiology, 2005 - 2006- Brown UniversityResidency, Neurology, 2002 - 2005
- Brown UniversityInternship, Internal Medicine, 2001 - 2002
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2001
Certifications & Licensure
MA State Medical License 2006 - 2025
RI State Medical License 2005 - 2024- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Clinical Neurophysiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Publications & Presentations
PubMed
- 8 citationsQuantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis.Michelle L Mellion, Per Widholm, Markus Karlsson, André Ahlgren, Rabi Tawil, Kathryn R Wagner, Jeffrey M Statland, Leo Wang, Perry B Shieh, Baziel G M van Engelen, Joo...> ;Neurology. 2022 Aug 30
- 14 citationsPhase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagementMichelle Mellion, Lucienne Ronco, Cécile Berends, Lisa Pagan, Sander Brooks, Michiel J van Esdonk, Emilie M J van Brummelen, Adefowope Odueyungbo, Lorin A. Thompson, M...> ;British Journal of Clinical Pharmacology. 2021 May 14
- 349 citationsSafety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn, Isabel Illa, Saiju Jacob, John Vissing, Ted M. Burns, John T. Kissel, Srikanth...> ;The Lancet. Neurology. 2017 Dec 1
- Join now to see all
Press Mentions
PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentApril 5th, 2022
Phase 1 Results Support Losmapimod as FSHD TreatmentMarch 26th, 2020
Fulcrum Therapeutics Announces Phase 1 Clinical Trial ResultsOctober 4th, 2019
Hospital Affiliations
Miriam HospitalProvidence, Rhode Island
Rhode Island HospitalProvidence, Rhode Island
Women & Infants Hospital of Rhode IslandProvidence, Rhode Island
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
